. Author manuscript; available in PMC: 2024 Sep 26.

Published in final edited form as: J Infect. 2022 Mar 1;84(5):658–667. doi: 10.1016/j.jinf.2022.02.032

Table 4.

hSBA titres in response to Ad-P1.7–2,4 and OMV vaccines. Individual mouse sera were tested using human complement. GMT with 95% CI for each group of mice for each time-point are shown. N = 8 BALB/c mice. ^∗ indicates a significant difference between the OMV prime (week 6) and OMV boost (week 14) sera P = .018 by Mann Whitney T test. ‘-’ indicates no boost (column 3) and not done (columns 2 and 4), as no SBA was expected for these test groups at these points.

P1.7–2,4 Vaccines
Prime vaccine	Week 6 hSBA	Boost vaccine	Week 14 hSBA
Naive	3.0 (1.0, 9.6)	–	–
Ad-P1.7–2,4	–	OMV- NZ98/254	58.7 (12.3,280.0)
OMV- NZ98/254	17.7 (5.1, 61.7)	OMV- NZ98/254	78.0* (48.0, 126.7)